Two weeks ago, Curevac presented disappointing interim data on its corona vaccine candidate.
Now it is finally clear: the vaccine falls far short of expectations.
Tübingen - This setback has begun, but now it is official: According to the final evaluation, the Corona * vaccine from the Tübingen biotech company Curevac has only a low level of effectiveness against the virus. The vaccine showed an overall effectiveness of 48 percent against Covid-19 diseases of any severity "in all age groups over 15 virus variants", the Tübingen-based company announced on Wednesday evening.
After a preliminary evaluation of the first study data a good two weeks ago, Curevac put the effectiveness of its vaccine candidate CVnCoV at 47 percent.
Investors reacted in horror after the publication of the first results in mid-June, and the company lost almost half of its value on the stock exchange.
Despite the setback, Curevac main shareholder Dietmar Hopp made a clear commitment to Curevac.
Hopp had
announced
to
Merkur.de
that
he would remain on board as an investor
.
Curevac: Over a year of development work
In total, Curevac had worked on the vaccine for over a year. But the results are disappointing. The protective effect of 48 percent applies to all age groups. In the 18 to 60 year old group, the significant protective effect is 53 percent. The vaccine protects against moderate or severe disease with an effectiveness of 77 percent. However, the agent always protects against hospitalization and corona death. On the stock exchange, Curevac went down again on Thursday. In the morning, the last badly shaken share traded around 15 percent lower at just under 53 euros.
Like the Mainz company Biontech, Curevac relies on a modern mRNA vaccine.
The Tübingen drug has long been considered extremely promising.
As recently as April, the company said it was hoping for approval from the European Medicines Agency (EMA) in May.
The federal government then planned the first vaccinations with the Curevac vaccine for the second quarter of 2021.
Curevac: Federal Health Minister Spahn is not planning a vaccine
In the meantime, Federal Health Minister Jens Spahn (CDU) no longer plans with Curevac.
According to a current overview, Biontech, Moderna, AstraZeneca and Johnson & Johnson want to deliver a total of 313.1 million cans by the end of the year.
Curevac no longer appears in the overview.